Meda Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Solna Sweden (1995)
Status: Acquired by Mylan (2016)

Organization Overview

First Clinical Trial
2018
NCT03599791
First Marketed Drug
1995
carisoprodol (soma)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

MEDA Pharma GmbH & Co. KG | Meda Pharma GmbH & Co. KG (A Mylan Company) | MEDA PHARMS

Active Ingredients

Marketed Drugs (7)

Key: Meda Pharmaceuticals (6) Acquired (1)

acetylsalicylic acid (aspirin) (1960)

butabarbital (neonal) (1978)

carisoprodol (soma) (1960)

codeine (Phenergan) (1960)

mesalamine (rowasa) (1990)

metoclopramide (reglan) (2005)

potassium iodide (thyro-block) (1979 NDA)

Drugs in Phase 4 Trials (4)

Key: Meda Pharmaceuticals (1) Acquired (3)

azelastine (astelin) (2 trials)

berberine (4 trials)

policosanol (5 trials)

red yeast (1 trial)

Drugs in Phase 3 Trials (13)

Key: Meda Pharmaceuticals (1) Acquired (12)

acetaminophen (tylenol) (1 trial)

acetylsalicylic acid (aspirin) (2 trials)

cholesterol (3 trials)

dexloxiglumide (1 trial)

fluticasone (cutivate) (1 trial)

glucosamine (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

lactose (1 trial)

megestrol (megace) (2 trials)

plantago ovata husk (2 trials)

ribavirin (virazole) (1 trial)

silibrin (4 trials)

silymarin (4 trials)

Drugs in Phase 2 Trials (4)

Key: Meda Pharmaceuticals (0) Acquired (4)

covid-evax (1 trial)

cr6086 (1 trial)

isphagula husk (1 trial)

sodium chloride (1 trial)

Drugs in Phase 1 Trials (1)

Key: Meda Pharmaceuticals (0) Acquired (1)

hemicellulose (1 trial)

Drugs in Other Trials (1)

Key: Meda Pharmaceuticals (0) Acquired (1)

isoflavone (1 trial)

Indications

Approved Indications


 

Anemia

Radioactive Pollutants

Experimental Indications (Clinical Trials, Phases 1-4)


 

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Seasonal (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 27
  • # of Trial APIs: 23